Loading...

CLRB CELLECTAR BIOSCIENCES INC Expansion Plans 8-K Filing

CLLC

CLRB

CELLECTAR BIOSCIENCES INC

(CLRB)

2025 8-K

Summary

Summary

Warrant Exercise Agreement

CMA Filing Update

Quarterly Financial Update

Product Expansion

Reverse Stock Split

Warrant Exercise

Financial Statements

Management Changes

Financial Results

Nasdaq Compliance Notice

Strategic Initiatives

Workforce Reduction

Q3 2024 Results

Consent Correction

Nasdaq Compliance

Q2 2024 Results

Restatement of Financial St...

Financial Condition

Warrant Exercise Inducement...

Accountant Change

Lease Agreement

Annual Meeting Approval

Earnings Reports

Financial Results Announcement

Notice from Nasdaq

Financial Results Announcement

Amendment to Certificate of...

Private Placement Offering

Financial Results Announcement

Data from Study of iopofosi...

Annual Meeting of Stockholders

Adjourned Meeting of Stockh...

Financial Results Announcement

Financial Results Announcement

Lease Agreement

External Links:

Cellectar Biosciences announced on October 6, 2025, that the EMA suggested a Conditional Marketing Authorization for iopofosine I 131 to treat Waldenstrom macroglobulinemia patients, though approval is not guaranteed.

AI Assistant

CELLECTAR BIOSCIENCES INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.